We are a developmental stage biotechnology company focusing on researching and developing drugs and diagnostic tests for products with a large commercial market potential as well as drugs which may qualify to treat rare diseases. We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”) and will therefore be subject to reduced public company reporting requirements.
Company profile
Ticker
IASO
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
10-Q
2019 Q3
Quarterly report
19 Nov 19
NT 10-Q
Notice of late quarterly filing
14 Nov 19
8-K
Entry into a Material Definitive Agreement
23 Sep 19
10-Q
2019 Q2
Quarterly report
19 Aug 19
NT 10-Q
Notice of late quarterly filing
14 Aug 19
10-Q
2019 Q1
Quarterly report
17 May 19
NT 10-Q
Notice of late quarterly filing
15 May 19
10-K
2018 FY
Annual report
24 Apr 19
NT 10-K
Notice of late annual filing
1 Apr 19
8-K
Entry into a Material Definitive Agreement
10 Jan 19
Latest ownership filings
No filings